Please login to the form below

Not currently logged in
Email:
Password:

Vascepa

This page shows the latest Vascepa news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug

CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug

In March 2020, a Nevada district court judge ruled that six patents on Vascepa (icosapent ethyl) – which were set to expire in 2030 – are invalid. ... At the same time, we will continue to meet the strong demand for Vascepa [.] in the US through our

Latest news

  • Amarin shares tumble following Vascepa patent loss Amarin shares tumble following Vascepa patent loss

    is approved by FDA, prevent launch of generic versions of Vascepa,” said John Thero, CEO of Amarin. ... The patent ruling only applies to Vascepa’s US patent exclusivity, with Amarin clarifying that its patents elsewhere in the world still stand.

  • Northsea Therapeutics raises $40m to develop fish oil NASH drug Northsea Therapeutics raises $40m to develop fish oil NASH drug

    The outlook for Northsea looks positive given Amarin’s success with its own fish oil-derived drug Vascepa (icosapent ethyl). ... This blockbuster indication has Amarin “aggressively launching” Vascepa in the US, after the company estimated expected

  • FDA okays Amarin’s Vascepa for cardiovascular risk reduction FDA okays Amarin’s Vascepa for cardiovascular risk reduction

    The approval is based on the results of the REDUCE-IT trial, which evaluated Vascepa in more than 8, 000 statin-treated adults with elevated cardiovascular risk. ... Analysts at Jefferies have previously said that approval based on the REDUCE-IT data

  • Amarin files fish oil-based heart drug Vascepa in Europe Amarin files fish oil-based heart drug Vascepa in Europe

    REDUCE-IT showed that Vascepa achieved a reduction of 25% in major adverse cardiovascular events (MACE) and a 20% reduction in deaths in high-risk patients. ... with Vascepa “major adverse cardiovascular events such as stroke, heart attack and

  • Amarin wins FDA advisory nod for Vascepa cardiovascular expansion Amarin wins FDA advisory nod for Vascepa cardiovascular expansion

    who have already suffered a CV event, Vascepa has the potential to reach over $1.5bn in annual sales, according to Wall Street analysts. ... Vascepa is positioned to be the first approved treatment to reduce cardiovascular events in the group of at-risk

More from news
Approximately 9 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...
Digital technologies: Pharma’s answer to achieving net zero emissions?
...